Skip to content

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Isoliquiritigenin attenuates doxorubicin-induced cardiomyopathy by alleviating mitochondrial dysfunction and oxidative damage through the Piezo1/Ca²⁺/Pdk4 signaling axis.

BACKGROUND Doxorubicin (DOX) is widely employed as an antineoplastic agent in clinical settings, yet its therapeutic utility is constrained by dose-dependent cardiotoxicity, partly resulting from oxidative injury to cardiomyocytes and impairment of mitochondrial function. Hence, there is an urgent imperative to develop...

Y. Wang, Dan Yang, Zhuo Liu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.